Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Currently there is no clear guidance for the treatment of moderate risk of pulmonary embolism. The aim of the study is to compare two different therapeutic modalities - standard anticoagulation versus thrombolytic treatment followed by anticoagulation in standard regimen as stated in the pulmonary embolism guidelines.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Ostrava
• Collaborators: Municipal Hospital Ostrava Fifejdy; Silesian Hospital Opava
• Treatments: Calcium heparin; Dalteparin; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Tissue Plasminogen Activator

Criteria

Inclusion Criteria:

• moderate risk pulmonary embolism as defined by the European Society of Cardiology /ESC/ guidelines

• signed informed consent

Exclusion Criteria:

• patient not willing to sigh informed consent

• absolute contraindication of thrombolysis

• inability to obtain meaningfull echocardiographic images¨

• pulmonary arterial hypertension

• known right ventricular failure